Search | IOVS | ARVO Journals

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Real-life outcomes of dexamethasone intravitreal implant (Ozurdex) in diabetic macular oedema for treatment-naive eyes compared to anti-VEGF non-responders at three months post-treatment

Ali Essam Ghareeb; Tiffany Lau; Mila Kishikova; Ajay Kotagiri; Ibrahim Masri; Jonathan Smith; Deepali Varma; David Steel; Maged Habib

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1047. doi:

ARVO Annual Meeting Abstract June 2021

Functional and Structural Outcomes of Patients with Diabetic macular oedema treated with multiple Ozurdex implants at 24 months – Real Life Data

Tiffany Lau; Ali Essam Ghareeb; Mila Kishikova; Ajay Kotagiri; Ibrahim Masri; Jonathan Smith; Deepali Varma; David Steel; Maged Habib

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1046. doi:

ARVO Annual Meeting Abstract July 2019

Real-life long-term outcomes for patients receiving intra-vitreal Aflibercept for neovascular age related macular degeneration (nAMD): five(5)-year follow-up

Ankur Mehta; Matthew Hartley; Majed Habib; Ajay Kotagiri; David Steel; Smith Jonathan; Deepali Varma

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):83. doi:

ARVO Annual Meeting Abstract July 2019

Predictive factors for successful treatment with intravitreal ocriplasmin

Michael Grinton; Jon Rees; Maged S Habib; Roxane Hillier; Daniela Vaideanu-Collins; Smith Jonathan; David Steel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2008. doi:

ARVO Annual Meeting Abstract July 2018

Real world data on the efficacy of Fluocinolone Acetonide (ILUVIEN) in eyes with diabetic macular oedema

Haifa A Madi; Yanmei Chen; David Steel; Jonathan Smith; Teresa Sandinha; Maged S Habib

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4817. doi:

ARVO Annual Meeting Abstract June 2017

Long-term real world outcomes in younger (under 60yrs) patients receiving anti-VEGF therapy for choridal neovascular membrane (CNVM).

Lyudmila Kishikova; Yewande Babalola; Maged S Habib; Deepali Varma; David Steel; Jonathan Smith; Maria T Sandinha; Ajay Kumar Kotagiri

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):418. doi:

ARVO Annual Meeting Abstract June 2017

Real life long term outcomes of patients receiving intra-vitreal Aflibercept for Neo-vascular age related macular degeneration (nAMD): three years follow up.

Yewande Babalola; Lyudmila Kishikova; Maged S Habib; Deepali Varma; Jonathan Smith; Maria T Sandinha; David Steel; Ajay Kotagiri

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):423. doi:

ARVO Annual Meeting Abstract June 2017

Real life experience of combined fixed-dosing and Treat and Extend protocols for the treatment of Diabetic Macular Oedema (DMO) with Anti-Vascular Endothelial Growth Factors (VEGF) agents

Karim El-Assal; Alex Stubbing-Moore; Caspar Geenen; Deepali Varma; Ajay Kumar Kotagiri; Jonathan Smith; David H W Steel; Maged S Habib

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1899. doi:

ARVO Annual Meeting Abstract June 2017

Real life experience of combined fixed-dosing and Treat and Extend protocols for intravitreal Aflibercept injections for Macular Oedema secondary to Central Retinal Vein Occlusion (CRVO)

Caspar Geenen; Karim El-Assal; David Steel; Deepali Varma; Ajay Kotagiri; Jonathan Smith; Maria T Sandinha; Maged S Habib

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3649. doi:

ARVO Annual Meeting Abstract September 2016

Are the initial treatment results of Ranibizumab for Diabetic Macular Oedema maintained at 1 year with Pro re nata protocol? A real life experience.

Ajay Kumar Kumar Kotagiri; Maged Habib; Alex Stubbing-Moore; Dalvir Bajwa; Deepali Varma; Maria Teresa Sandinha; Jonathan Smith; David Steel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2099. doi:

Advertisement